U.S. markets closed
  • S&P 500

    -54.85 (-1.51%)
  • Dow 30

    -500.10 (-1.71%)
  • Nasdaq

    -161.89 (-1.51%)
  • Russell 2000

    -10.21 (-0.61%)
  • Crude Oil

    -1.49 (-1.83%)
  • Gold

    -0.30 (-0.02%)
  • Silver

    +0.30 (+1.62%)

    -0.0018 (-0.19%)
  • 10-Yr Bond

    +0.0570 (+1.52%)

    +0.0043 (+0.38%)

    +0.2770 (+0.19%)

    -211.22 (-1.08%)
  • CMC Crypto 200

    +0.06 (+0.01%)
  • FTSE 100

    +12.22 (+0.18%)
  • Nikkei 225

    -484.84 (-1.83%)

On National Donor Day, CareDx Applauds Patient Advocacy Efforts Aimed at Increasing Donations for the Thousands of Patients Waiting for a Transplant

·4 min read
CareDx, Inc.
CareDx, Inc.

More than 100,000 Americans Are on the National Transplant Waiting List and Nearly 20 Die Each Day Waiting for an Organ Transplant They Desperately Need

SOUTH SAN FRANCISCO, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that in commemoration of National Donor Day, held on February 14, it is doing its part to increase public awareness of the serious need for more donations – organ, eye, tissue, blood, platelets and marrow – by providing support to national patient advocacy groups such as Donate Life America, National Kidney Foundation, and The National Minority Organ Tissue Transplant Education Program, which along with other organization are championing more supply for this life-sparing need.

“At CareDx we are 100 percent committed to supporting the transplant patient journey. It starts with a transplant and with more than 100,000 patients waiting for an organ transplant alone, patient advocacy and legislative efforts are critical in addressing this serious unmet need,” said Reg Seeto, CEO and President of CareDx. “We have supported important legislative policies including the Living Donor Protection Act to promote live organ donations and protect donors from discrimination, and recently made sure that our patient’s voices were heard when CMS requested public comments by sharing their insights on the need for greater public awareness around organ donations and earlier waitlist inclusion.”

“Observed every year on February 14, National Donor Day is a day to spread awareness and education about organ, eye and tissue donation,” said David Fleming, President and CEO of Donate Life America. “There is a serious shortage of lifesaving organs and my hope for today’s commemoration is that, collectively, we’ve raised more awareness that has led to more Americans registering as donors. We thank CareDx, our other partners and donors for helping Donate Life America achieve our mission of increasing the number of donated organs available to save lives.”

To register to be an organ, eye and tissue donor, please visit www.RegisterMe.org or HRSA.

About CareDx – The Transplant Company
CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Forward Looking Statements
This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with CareDx’s support to national patient advocacy groups in commemoration of National Donor Day (the “Support”). These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of the Support; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed by CareDx with the SEC on February 24, 2021, the quarterly report on Form 10-Q for the first quarter of 2021 ended on March 31, 2021 filed by CareDx with the SEC on May 5, 2021, the quarterly report on Form 10-Q for the second quarter of 2021 ended on June 30, 2021 filed by CareDx with the SEC on July 29, 2021, the quarterly report on Form 10-Q for the third quarter of 2021 ended on September 30, filed by CareDx with the SEC on October 28, 2021, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.


CareDx, Inc.
Sasha King
Chief Marketing Officer

Investor Relations
Ian Cooney
(415) 722-4563